13F Holdings
中文EN

SRZN Surrozen, Inc./DE

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1824893 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY192.1%
TTM net income YoY-349.0%
TTM EPS YoY-138.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-485.4%
Net margin-3,706.4%
FCF margin-292.3%
EBITDA margin-483.4%

Returns

ROE—
ROA-384.3%
ROIC (approx.)—
Asset turnover0.10x

Leverage & solvency

Liabilities / assets407.8%
Debt / equity—
Current ratio7.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-354.2%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.48M$10.65M$0$12.50M$0
R&D expense$29.36M$21.13M$27.23M$37.01M$40.18M
SG&A expense$16.20M$15.06M$15.80M$19.83M$14.21M
Operating income-$42.09M-$25.54M-$45.78M-$44.34M-$54.39M
Pretax income-$242.03M-$63.56M———
Income tax$0$0$0$0$0
Net income-$242.03M-$63.56M-$43.04M-$36.00M-$54.65M
EBITDA-$41.55M-$24.10M-$43.87M-$42.38M-$52.33M
EPS (basic)-32.37-21.67-21.33-15.56-2.21
EPS (diluted)-32.37-21.67-21.33-15.56-2.21
Weighted avg. shares (diluted)7,4782,9332,0182,31424,689
Balance sheet
Cash & equivalents$89.25M$35.25M$36.73M$25.09M$33.50M
Short-term investments——$0$51.15M$68.76M
Receivables$0$2.04M$2.15M$1.98M$0
Current assets$91.56M$38.93M$41.13M$81.31M$105.19M
PP&E, net$433,000$562,000$1.97M$3.63M$4.79M
Total assets$98.73M$48.47M$46.08M$89.44M$137.17M
Current liabilities$9.93M$7.32M$7.15M$9.73M$13.57M
Total liabilities$286.49M$69.85M$8.14M$13.43M$27.47M
Shareholders' equity-$187.76M-$21.38M$37.94M$76.00M$109.70M
Shares outstanding9.78M3.26M2.06M2.01M35.03M
Cash flow statement
Operating cash flow-$30.24M-$17.63M-$40.36M-$44.15M-$48.81M
Capital expenditure$128,000$26,000$398,000$728,000$1.27M
Free cash flow-$30.37M-$17.65M-$40.76M-$44.87M-$50.08M
Investing cash flow-$128,000-$26,000$51.72M$38.31M-$77.71M
Financing cash flow$85.05M$16.18M$276,000-$2.56M$124.63M
Depreciation & amortization$537,000$1.44M$1.91M$1.96M$2.07M
Stock-based compensation$3.83M$4.11M$4.37M$4.52M$2.32M
Share buybacks——$0$2.61M$0

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.